Non-small Cell Lung Cancer with Concomitant EGFR, KRAS, and ALK Mutation: Clinicopathologic Features of 12 Cases
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Although epidermal growth factor receptor (EGFR), v-Ki-ras2 Kirsten rat sarcoma viral oncogene (KRAS), and anaplastic lymphoma kinase (ALK) mutations in non-small cell lung cancer (NSCLC) were thought to be mutually exclusive, some tumors harbor concomitant mutations. Discovering a driver mutation on the basis of morphologic features and therapeutic responses with mutation analysis can be used to understand pathogenesis and predict resistance in targeted therapy. Methods: In 6,637 patients with NSCLC, 12 patients who had concomitant mutations were selected and clinicopathologic features were reviewed. Clinical characteristics included sex, age, smoking history, previous treatment, and targeted therapy with response and disease-free survival. Histologic features included dominant patterns, nuclear and cytoplasmic features. Results: All patients were diagnosed with adenocarcinoma and had an EGFR mutation. Six patients had concomitant KRAS mutations and the other six had ALK mutations. Five of six EGFR-KRAS mutation patients showed papillary and acinar histologic patterns with hobnail cells. Three of six received EGFR tyrosine kinase inhibitor (TKI) and showed partial response for 7–29 months. All six EGFR-ALK mutation patients showed solid or cribriform patterns and three had signet ring cells. Five of six EGFR-ALK mutation patients received EGFR TKI and/or ALK inhibitor and four showed partial response or stable disease, except for one patient who had acquired an EGFR mutation. Conclusions: EGFR and ALK mutations play an important role as driver mutations in double mutated NSCLC, and morphologic analysis can be used to predict treatment response.
Abstract
Background: Although epidermal growth factor receptor (EGFR), v-Ki-ras2 Kirsten rat sarcoma viral oncogene (KRAS), and anaplastic lymphoma kinase (ALK) mutations in non-small cell lung cancer (NSCLC) were thought to be mutually exclusive, some tumors harbor concomitant mutations. Discovering a driver mutation on the basis of morphologic features and therapeutic responses with mutation analysis can be used to understand pathogenesis and predict resistance in targeted therapy. Methods: In 6,637 patients with NSCLC, 12 patients who had concomitant mutations were selected and clinicopathologic features were reviewed. Clinical characteristics included sex, age, smoking history, previous treatment, and targeted therapy with response and disease-free survival. Histologic features included dominant patterns, nuclear and cytoplasmic features. Results: All patients were diagnosed with adenocarcinoma and had an EGFR mutation. Six patients had concomitant KRAS mutations and the other six had ALK mutations. Five of six EGFR-KRAS mutation patients showed papillary and acinar histologic patterns with hobnail cells. Three of six received EGFR tyrosine kinase inhibitor (TKI) and showed partial response for 7–29 months. All six EGFR-ALK mutation patients showed solid or cribriform patterns and three had signet ring cells. Five of six EGFR-ALK mutation patients received EGFR TKI and/or ALK inhibitor and four showed partial response or stable disease, except for one patient who had acquired an EGFR mutation. Conclusions: EGFR and ALK mutations play an important role as driver mutations in double mutated NSCLC, and morphologic analysis can be used to predict treatment response.
참고문헌 (27)
- Lynch TJ, "Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib", N Engl J Med, 350, pp.2129~2139 (2004)
- Riely GJ, "KRAS mutations in non-small cell lung cancer", Proc Am Thorac Soc, 6, pp.201~205 (2009)
- Kwak EL, "Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer", N Engl J Med, 363, pp.1693~1703 (2010)
- Soda M, "Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer", Nature, 448, pp.561~566 (2007)
- Siegel RL, "Cancer statistics, 2015", CA Cancer J Clin, 65, pp.5~29 (2015)
- Paez JG, "EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy", Science, 304, pp.1497~1500 (2004)
- Lindeman NI, "Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology", J Thorac Oncol, 8, pp.823~859 (2013)
- Narita Y, "Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer", Lung Cancer, 90, pp.71~77 (2015)
- Gainor JF, "ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer", Clin Cancer Res, 19, pp.4273~4281 (2013)
- Tiseo M, "EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations", Lung Cancer, 71, pp.241~243 (2011)
- Lee JK, "Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation", Lung Cancer, 77, pp.460~463 (2012)
- Baldi L, "Concomitant EGFR mutation and ALK rearrangement in lung adenocarcinoma is more frequent than expected: report of a case and review of the literature with demonstration of genes alteration into the same tumor cells", Lung Cancer, 86, pp.291~295 (2014)
- Won JK, "Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor", Ann Oncol, 26, pp.348~354 (2015)
- Paik JH, "Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization", Thorac Oncol, 6, pp.466~472 (2011)
- Bai H, "Detection and clinical significance of intratumoral EGFR mutational heterogeneity in Chinese patients with advanced non-small cell lung cancer", PLoS One, 8, pp.E54170~ (2013)
- Yang JJ, "Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation", Clin Cancer Re, 20, pp.1383~1392 (2014)
- Choi YL, "EGFR mutation testing in patients with advanced non-small cell lung cancer: a comprehensive evaluation of real-world practice in an East Asian tertiary hospital", PLoS One, 8, pp.E56011~ (2013)
- Sun Y, "Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases", J Clin Oncol, 28, pp.4616~4620 (2010)
- Shaw AT, "Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK", J Clin Oncol, 27, pp.4247~4253 (2009)
- Ninomiya H, "Correlation between morphology and EGFR mutations in lung adenocarcinomas significance of the micropapillary pattern and the hobnail cell type", Lung Cancer, 63, pp.235~240 (2009)
- Rekhtman N, "KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma", Mod Pathol, 26, pp.1307~1319 (2013)
- Nishino M, "Histologic and cytomorphologic features of ALK-rearranged lung adenocarcinomas", Mod Pathol, 25, pp.1462~1472 (2012)
- Ha SY, "Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR", Oncotarget, 6, pp.5465~5474 (2015)
- 한정호, "Analysis of Histologic Features Suspecting Anaplastic Lymphoma Kinase (ALK)-Expressing Pulmonary Adenocarcinoma", Journal of Pathology and Translational Medicine, 49(4), pp.310~317 (2015), 대한병리학회[DOI]
- Sasaki T, "A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors", Cancer Res, 71, pp.6051~6060 (2011)
- Kim S, "Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer", J Thorac Oncol, 8, pp.415~422 (2013)
- Kuo YW, "Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation", J Thorac Oncol, 5, pp.2039~2040 (2010)